Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1749-6632.1965.tb18983.x | DOI Listing |
Cancer Biomark
October 2024
Department of Neurology, Chenzhou First People's Hospital, Chenzhou, China.
Background: Radioiodine-131 (I-131) therapy is the common postoperative adjuvant therapy for differentiated thyroid cancer (DTC) However, methods to evaluate the efficacy and toxicity of I-131 on DTC are still lacking.
Objective: To evaluate the association between vitamin D receptor (VDR) gene polymorphisms and the efficacy and toxicity of I-131 in DTC patients.
Methods: A total of 256 DTC patients who received I-131 therapy were enrolled.
Asian Pac J Cancer Prev
March 2024
Directorate of Nuclear Facility Management, National Research and Innovation Agency, Serpong, Indonesia.
Objective: The purpose of this study was to analyze the effect of oral administration of radioiodine (I-131) on the immune responses (interleukin 6 and 10) as biodosimetry markers and to support clinical trials of I-131 solution.
Methods: The design of this study was an in vivo experimental study using twenty-seven male rats (Rattus norvegicus strain Sprague-Dawley) given 100 μL of I-131 solution at a dose of 260 μCi. Blood plasma was taken at 0.
Endocrine
August 2024
Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Environ Res
June 2024
School of Bio-Chemical Engineering and Technology, Sirindhorn International Institute of Technology (SIIT), Thammasat University, P.O Box 22, Pathum Thani 12121, Thailand. Electronic address:
In aquatic settings, radioactive iodine from nuclear waste can exist as iodate (IO). This study explored the efficiency and mechanism of IO adsorption by minimally modified anthocyanin-based adsorbents. Pomegranate peels and mangosteen pericarps were selected from an initial screening test and could remove over 70% of 10 mg/L IO.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!